Table 1 Distribution of the patients according to demographic data, echocardiography findings, stroke, thromboembolic and bleeding risk stratification, concomitant diseases
Patients | Warfarin group | NOACs group | |
|---|---|---|---|
(n, %) | (n, %) | (n, %) | |
Male | 277 (64.1%) | 193 (63.1%) | 84 (66.7%) |
Female | 155 (35.9%) | 113 (36.9%) | 42 (33.3%) |
Age, years ± SD | 65.1 ± 11.5 | 64.6 ± 11.1 | 64.9 ± 12.5 |
CHA2DS2-VASc value ± SD | 3.5 ± 1.5 | 3.6 ± 1.6 | 3.4 ± 1.5 |
HAS-BLED value ± SD | 0.9 ± 0.9 | 1.1 ± 0.9 | 0.9 ± 0.9 |
HF | 330 (76.4%) | 238 (77.8%) | 92 (73.0%) |
AH | 399 (92.4%) | 280 (91.5%) | 119 (94.4%) |
CAD | 216 (50.0%) | 164 (53.6%) | 52 (41.3%) |
Previous stroke or TIA | 23 (5.3%) | 21 (6.9%) | 2 (1.6%) |
DM | 54 (12.5%) | 41 (13.4%) | 13 (10.3%) |
BMI 18.5 – 24.9 kg/m2 | 59 (14.5%) | 39 (13.5%) | 20 (16.8%) |
BMI 25.0 – 29.9 kg/m2 | 138 (33.9%) | 95 (33.0%) | 43 (36.1%) |
BMI ≥30 kg/m2 | 209 (51.4%) | 153 (53.0%) | 56 (47.0%) |
LVH | 29 (6.7%) | 19 (6.2%) | 10 (7.9%) |
LVEF ≥50% | 219 (50.7%) | 142 (46.4%) | 77 (61.1%) |
LVEF 41–49% | 134 (31.0%) | 99 (32.4%) | 35 (27.8%) |
LVEF ≤40% | 79 (18.3%) | 65 (21.2%) | 14 (11.1%) |
No LA enlargement | 73 (16.9%) | 41 (13.4%) | 32 (25.4%) |
I° LA enlargement | 126 (29.2%) | 91 (29.7%) | 35 (27.8%) |
II° LA enlargement | 126 (29.2%) | 94 (30.7%) | 32 (25.4%) |
III° LA enlargement | 107 (24.8%) | 80 (26.1%) | 27 (21.4%) |
Total | 432 (100%) | 306 (70.8%) | 126 (29.2%) |